Tarsa, which is backed by Novo and Unigene, raises $28m.

The maker of electrocardiographic mapping technology raises the funds, slightly more than a year after winning backing from Japan-based cardiovascular device distributor DVX.

The biotechnology company backed by a Mitsubishi unit, which treats patients with excess iron in their blood, sells for up to $325m

The top-line growth in 2011 comes after the healthcare software provider secured its first institutional investment the Blue Cross and Blue Shield Association's venture fund and its manager Sandbox Industries.

Motorola and Cisco Systems are selling shares in the flotation of the provider of mobile technology for hospitals.

The corporate venturing unit of Siemens supports the US-based cancer treatment company's third round after it won Food and Drug Administration approval for one of its products.

Boston Scientific exercises an option it acquired in 2004 as part of a corporate venturing deal to buy heart treatment company Cameron Health for up to $1.35bn.

Neurophage extends its series B round with backing from healthcare companies Insitut Merieux and Shire.

The Roche Venture Fund-backed biotechnology company appoints the former executive chairman of BiPar Sciences, which was sold for $500m in 2009, as its chairman.

Genetic diseases company 4s3 Bioscience lands funding from a healthcare subsidiary of the family office of the wealthy Pritzker and Vlock families.